Abstracts tagged "Lupus and pregnancy"

Abstract Number: 2291 • 2019 ACR/ARP Annual Meeting
Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus
Stephen Balevic¹, Michael Cohen-wolkowiez ², Amanda Eudy ³, Mara Becker ⁴, Laura Schanberg ⁵ and Megan Clowse ³, ¹Duke University, Hillsborough, NC, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke Children's Hospital, Durham, NC, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Pregnancies in women with systemic lupus erythematosus (SLE) often result in preterm birth. Active disease during pregnancy significantly increases the risks for these poor…
Abstract Number: 2531 • 2015 ACR/ARHP Annual Meeting
Hematologic Disorder during Pregnancy Associated with Adverse Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus
Sara K. Tedeschi¹, Hongshu Guan², Alexander Fine², Bing Lu¹, Karen H. Costenbader¹ and Bonnie Bermas¹, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies have found a relationship between overall systemic lupus erythematosus (SLE) activity and adverse pregnancy outcomes. We sought to investigate whether specific types…
Abstract Number: 2931 • 2015 ACR/ARHP Annual Meeting
Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?
Chi Chiu Mok¹, Sau Mei Tse¹, Ling Yin Ho² and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate whether pregnancy is a risk factor for the onset of SLE in women of the reproductive age.Methods: Female patients who had first…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].